Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
US commission recommends federal research revamp to avoid losing global biotech edge
(16h)
FTC outlines antitrust case against Edwards' $945M JenaValve acquisition
(17h)
AbbVie launches lab space award program for Quebec biotechs
(19h)
GE HealthCare presents photon-counting CT system for FDA review
(20h)
Lawmakers probe FDA’s new priority voucher program, cite corruption and rushed review concerns
(21h)
Novo Nordisk expands pivotal amycretin program after dual agonist shines in diabetes
(23h)
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
(1d)
J&J MedTech bolsters stroke R&D programs in Ireland
(1d)
Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program
(1d)
Abbott to replace certain FreeStyle Libre 3 CGMs after incorrect readings and death reports
(1d)
Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease
(1d)
Versant's Dayra dawns with $50M Biogen pact, oral macrocyclic peptide mission
(1d)
J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2
(1d)
Solventum to buy Acera Surgical for up to $850M, repurchase $1B in stock
(2d)
Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
(2d)
In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation
(4d)
CDC instructs researchers to end all monkey studies by year end: Science
(4d)
FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process
(4d)
Roche inks $200M+ licensing pact for Freenome's cancer screening blood tests
(4d)
GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement
(4d)
BioPharma Dive
Novartis wins approval to use SMA gene therapy in older patients
(20h)
Gilead scoops up a preclinical cancer program
(21h)
How do Big Pharma employees rate their CEOs?
(21h)
Kelun, Merck tout ADC as potential first-line treatment in lung cancer
(21h)
Bayer’s experimental blood-thinner notches trial win in stroke prevention
(1d)
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s trials
(1d)
FDA probes effects of Takeda rare disease drug after patient death
(1d)
Biogen strikes deal with Versant-backed biotech to expand immune portfolio
(1d)
APOE4 and CRISPR are reframing Alzheimer’s Risk
(2d)
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
(4d)
FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M
(4d)
GSK, Anaptysbio sue each other over Jemperli revenue
(5d)
A brain biotech’s top drug fails against MS
(5d)
Moderna secures $1.5B lifeline as it looks to break even in 2028
(5d)
With new approvals, Regeneron’s higher-dose Eylea gets more competitive
(5d)
Aspen raises $115M for a Parkinson’s stem cell treatment
(5d)
Abbott to acquire Exact Sciences for about $21B
(5d)
Roche inks deal for rights to Freenome cancer tests outside US
(5d)
Agios shares fall on mixed sickle cell results for blood disease drug
(6d)
UnitedHealth adds former FDA commissioner Scott Gottlieb to board
(6d)
Endpoints News
Sanofi headquarters raided in broader French tax fraud investigation
(33m)
Kallyope scraps one of two mid-stage migraine drugs
(1h)
Otsuka’s anti-APRIL antibody gets FDA approval for kidney disease IgAN
(11h)
CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks
(13h)
What a team of ex-Amazon employees are building next in healthcare
(18h)
Pharma faces deadline to bring IRA fight to Supreme Court as first set of negotiated prices looms
(18h)
FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program
(20h)
Novo Nordisk’s amycretin cuts body weight, blood sugar in Phase 2 diabetes trial
(21h)
Novartis plans to lay off 550 workers at Swiss factory
(22h)
FDA approves Novartis’ Itvisma for older patients with spinal muscular atrophy
(1d)
Novartis was the sole bidder in $12B deal to buy Avidity
(1d)
FDA's Pazdur is said to raise questions about commissioners actions, new voucher
(1d)
UK-US drug pricing deal could come as early as this week, sources say
(1d)
#ASH25: Kelonia’s first in vivo CAR-T data; Lilly, J&J and Novartis spell out Phase 3 wins
(1d)
J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study
(1d)
Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
(1d)
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
(1d)
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics
(2d)
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
(2d)
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
(2d)
BioSpace
Are Animals Out? How NAMs Are Changing the Rules of the Game
(5h)
Budget Cuts Are Hobbling American Innovation
(6h)
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
(20h)
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal
(20h)
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
(21h)
Lilly Redefines the Pharma Mega-Blockbuster
(22h)
Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could "Shift Paradigm" in Myeloma
(22h)
Pazdur Questions Legality, Safety of FDA’s Expedited Drug Approvals Programs
(22h)
Former DARPA Official Jackson Named ARPA-H Head
(23h)
As CGT Struggles To Scale, FDA's New Designation Could Smooth Post-Approval Pivots
(1d)
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
(1d)
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
(1d)
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
(2d)
NervGen’s Peptide Achieves Nervous System Repair in Phase II Spinal Cord Injury Study
(2d)
Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data
(2d)
FDA Frictions Continue as White House Denies Promotion to Makary’s Aide
(2d)
Cell and Gene Therapy Will Transform Lives—If We Let It
(2d)
FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’
(2d)
FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy
(4d)
6 Biotechs With a Shot at the FDA’s Platform Technology Designation
(4d)
STAT News
Proposal to remove advanced nursing from list of ‘professional’ degrees is short-sighted and dangerous
(2h)
What if RFK Jr. reacted to his cousin’s terminal cancer as JFK reacted to his baby’s death?
(2h)
Why beagles are the No. 1 dog for medical research
(2h)
Why my colleagues and I are undertaking an independent review of the hepatitis B birth dose
(2h)
Trump administration quietly unveils new round of Medicare-negotiated drug prices
(11h)
FDA approves Otsuka kidney disease therapy
(14h)
Major health insurers like Humana, UnitedHealth are cutting broker commissions to avoid costly Medicare enrollees
(14h)
Therapy chatbot study lands with a thud
(18h)
We’re reading about a Novo next-gen diabetes drug, a Novartis gene therapy, and more
(22h)
The hidden reason lung cancer screening is not working
(1d)
I have long Covid. Don’t call my chronic disease a ‘journey’
(1d)
Federal biotech commission calls for retooling of scientific research infrastructure
(1d)
Trump weighs plan to extend extra ACA subsidies for two years
(1d)
Everyone picked a health plan, everyone’s miserable
(1d)
Medicare backs off plan for quicker clawback of $7.8 billion from hospitals
(1d)
Lilly hits trillion-dollar valuation as GLP-1 era peaks
(1d)
J&J’s novel Alzheimer’s drug fails in key trial, dimming hopes for a hot target
(1d)
We’re reading about failed Novo Alzheimer’s trials, favorable Bayer stroke results, and more
(1d)
A former scientific leader at CDC died at 94
(2d)
Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
(2d)
BioPharma Trend
Ginkgo Bioworks Launches Open-Source Pharmacology Framework for AI Drug Discovery
(6d)
Antheia and TAPI Announce Strategic Partnership to Scale Biosynthetic Pharmaceutical Manufacturing
(6d)
Terray Launches Experiment-Driven Machine Learning Platform for Small-Molecule Discovery
(1w)
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(2w)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(3w)
Companies Making Automated Drug Discovery a Reality
(3w)
Five Companies Leading the Way in 3D Bioprinting
(3w)
Roche and Manifold Bio's $55M-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases
(3w)
Flatiron Health Launches Six AI Blood Cancer Datasets Covering 505,000 Patients
(4w)
Recursion Unveils Whole-Genome Microglia Map With Roche and Genentech
(4w)
New Foundation Model Reportedly Surpasses AlphaFold 3 in Drug-Protein Binding Prediction
(4w)
Flagship Unveils AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program
(1mo)
Iambic Reports Early Clinical Activity of AI-Designed HER2 Inhibitor
(1mo)
AstraZeneca and AI-Powered Immune Mapping Company Immunai Sign Up To $85M IBD Target Agreement
(1mo)
Takeda Expands AI-Driven Antibody Design Partnership with Nabla Bio in a Billion-Dollar Deal
(1mo)
AI and CRISPR—converging revolutions in biomedicine?
(1mo)
Sanofi Licenses BenchSci’s Neurosymbolic AI for Global Preclinical RD
(1mo)
AI Model Built on Transformer Architecture Maps 1,300 Mouse Brain Regions in Data-Driven Atlas
(1mo)
AstraZeneca Signs $555 Million AI Deal With Algen For CRISPR Therapies
(1mo)
Singapore’s Nanyang Biologics Plans to Go Public on Nasdaq in US $1.5 Billion SPAC Deal
(1mo)
Drug Channels
The Hidden Burdens of Cancer Care: When Insurers Override Doctors
(6d)
Drug Channels News Roundup, November 2025: PBM Revolution, Cuban’s Stelara Challenge, Express Scripts’ Price Games, U.S. Drug Spending Reality, and the AFP Reckoning
(1w)
The $700 Copay That Changed Everything
(2w)
Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses
(2w)
Drug Channels Outlook 2026: Live Webinar with Adam J. Fein, Ph.D., on PBMs, Part D, DTC Strategies, Drug Policy Trends, and More
(2w)
Hubs, AI, and the New Era of Revenue Protection in Patient Access
(3w)
As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact
(4w)
Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble
(4w)
Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting
(4w)
Let’s Be DIRECT: We Have an Access and Affordability Problem to Solve
(1mo)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices
(1mo)
Informa Connect’s Trade and Channel Strategies
(1mo)
Why Site of Care Is the Hidden Barrier in Neurology’s Bright Pipeline
(1mo)
NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(1mo)
Informa Connect’s Pharma/Biotech GTN Summit
(1mo)
Direct-to-Patient 2.0: Why Today’s DTP Programs Can’t Scale—and What Pharma Must Do Next
(1mo)
The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip (rerun)
(1mo)
2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)
(1mo)
The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market (rerun)
(1mo)
Informa Connect’s PBM Contracting Summit
(1mo)
European Biotechnology Magazine
Novo Nordisk’s semaglutide fails in Alzheimer’s
(2h)
Gilead acquires Sprint Bioscience TREX1 programme
(1d)
AGC Biologics to manufacture dual AAV therapies for AAVantgarde
(4d)
Melatonin: a promising new approach in Alzheimer’s treatment
(4d)
Giredestrant demonstrates efficacy in early-stage breast cancer
(1w)
Avanzanite secures €32m Series A funding
(1w)
Millions Flow Into Captain T Cell as Berlin’s Cell Therapy Scene Defies the Gloom
(1w)
MitoRx Therapeutics advances next-generation obesity therapy
(1w)
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
(1w)
Medicxi announces new €500m biotech investment fund
(1w)
Virometix: US$15m for Synthetic Vaccines
(2w)
Antibodies: Cornerstone of ADC precision and efficacy
(2w)
Scripta Therapeutics raises $12m to flip the script on drug discovery
(2w)
AZ’s baxdrostat mets endpoint in resistant hypertension
(2w)
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
(2w)
From method validation to the life-cycle
(2w)
SciVario®twin: One Controller for All Your Needs
(2w)
Breakthrough study reveals stability key for mRNA
(2w)
Semaglutide and tirzepatide significantly improve heart health
(2w)
CDMO: An SAP S/4HANA transformation in
(3w)
Drug Hunter
paltusotine
(18h)
October 2025 Patent Highlights
(4d)
October 2025
(5d)
elinzanetant (NT-814)
(6d)
TCIPs: Heterobifunctional Compounds for Gene Activation
(6d)
daraxonrasib (RMC-6236)
(1w)
Patent Target Brief: Macrocycles Targeting the LAG3:MHC-II Protein–Protein Interactions
(1w)
taletrectinib
(2w)
Will a New Binding Approach Reinvigorate Caspase-1 as a Therapeutic Target for Autoimmune Disorders?
(2w)
nerandomilast (BI 1015550)
(2w)
monepantel (NUZ-001)
(2w)
sepiapterin (PTC 923)
(2w)
CHF6333
(3w)
Reimagining Druggability Using Chemoproteomic Platforms
(3w)
Patenting Strategies for Small Molecule Drugs
(3w)
PAD Inhibitors: Multiple Approaches Have Striven to Make it to Clinical Development
(3w)
AG-270
(3w)
zoliflodacin (ETX-0914)
(3w)
Oncogenic Hyperactivation Lethality: Moving from Concept to Clinic
(3w)
PRT3645
(4w)
Labiotech.EU
11 neuroscience biotech companies you should know about
(22h)
Six key obesity deals in 2025
(5d)
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
(5d)
Eight CAR-T cell therapy companies you should know about
(7d)
Twice the punch: The emergence of dual-payload antibody and peptide drug conjugates
(1w)
On the fast track to the clinic: early decisions in drug development
(1w)
Precision psychiatry is the future of mental healthcare
(1w)
10 gene therapy companies you should know about
(2w)
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
(2w)
iGEM Jamboree: leap into the synthetic biology future
(2w)
Biosimilars: a vital remedy for Europe’s healthcare challenges
(2w)
Swiss biotech going strong in 2024: 19 companies to put on your radar
(2w)
New cancer cell discovery sheds light on childhood blood cancer
(2w)
BIO Europe partnering: Australian biotech companies share their experiences
(2w)
Top biotech deals in October 2025
(3w)
Next‑generation UTI diagnostics: delivering results in just 35 minutes
(3w)
Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring
(3w)
Treating endometriosis: what lies ahead?
(3w)
The biggest biotech funding rounds in October 2025
(3w)
Rethinking protein production: Why Pichia pastoris is gaining ground in biotech
(3w)
Bio IT World
Follow the Money: Enveloped Delivery Vehicle Technology, Oral Medication for Inflammatory, Neurological Diseases, More
(1d)
Eli Lilly to Open Lab in Philadelphia, QIAGEN to Acquire Parse Biosciences, Novartis Expands to North Carolina
(2d)
Ginkgo Datapoints Launches Virtual Cell Pharmacology Initiative
(5d)
The Women’s Health Gap: 5 Cautionary Tales of Clinical Blunders
(1w)
ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas
(1w)
Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?
(2w)
Why Overlooking Female Biology Still Impairs Drug Development
(2w)
United Genetic, Epigenetic Readouts From The Same DNA Molecule
(2w)
Revolutionizing ADC Manufacturing: How Single-Use Technologies Are Reshaping Biopharma Efficiency and Safety
(3w)
DNA Nanotech Brings Precision Drug Monitoring to At-Home Use
(3w)
PacBio Aims for Sub-$300 Genomes with Reusable SMRT Cells
(3w)
NVIDIA Unveils Quantum-AI Integration and Record-Breaking Blackwell Architecture at GTC 2025
(4w)
SandboxAQ Releases New AI Model, Illumina Launches New Business, Thermo Fisher’s New Analyzer
(4w)
Follow the Money: Potential Best-in-Category Weight Loss Drug Tubulis’ ADC Advancement, Trojan Horse Treatment for Cancer
(4w)
AI Model Turns Health Data Into Disease Forecasts
(1mo)
Multiomics Approach Predicts Rheumatoid Arthritis Before First Joint Swelling
(1mo)
Longitude Prize on ALS Announces Judge Panel
(1mo)
uniQure’s Huntington’s Disease Trial Shows Promising Results
(1mo)
New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors
(1mo)
TOR Inhibitors Could One Day Be Multi-Purpose Healthspan Drugs
(1mo)
GEN News
Mapping the Neural Mechanism Behind Social Isolation Following Immune Challenge
(11h)
Backbone Potential: Actuate’s Elraglusib Shows Promise vs. Pancreatic Cancer
(12h)
Industry-Academia Collaboration Formed to Improve Cell and Gene Therapy Manufacturing
(12h)
Cyanobacterial Pigments Advance Biomedicine Through Smarter Bioprocessing
(19h)
Microbiome Analysis Sees Cleanroom Contaminants Other Methods Miss
(19h)
New Standards Aim to Support Gene Therapy Manufacturers
(19h)
Precipitation Offers Low-Cost Solution for Monoclonal Manufacturing
(19h)
Proteome-Wide AI Model Supports Rare Disease Diagnosis Using Evolution
(20h)
AstraZeneca Plans $2 Billion Biomanufacturing Investment in Maryland
(23h)
Metformin’s Surprising Potential Benefits in Type 1 Diabetes Therapy
(1d)
HIV Vaccine Efforts Strengthened with Advanced AI at Scripps
(1d)
Cellarity’s AI Model Improves Drug Safety by Predicting Liver Injury
(1d)
StockWatch: Avadel Sparks Bidding War; Agios Plummets 51% on Phase III Data
(2d)
Immune Cell Profiling in Type 1 Diabetes Identifies Changes in Memory T Cells and B Cells
(3d)
Ginkgo Datapoints Launches Virtual Cell Initiative for AI Drug Discovery
(4d)
Novartis Plans to Build Flagship Manufacturing Hub in North Carolina
(4d)
HIV Integrase Captured by Cryo-EM in Two Structural States
(4d)
New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC
(5d)
Improving Astrocyte Function Shows Promise for Alzheimer’s
(5d)
DNA Damage Sensor Reveals Repair in Real Time
(5d)
Cure Today
Understanding Stage 1 Polycythemia Vera: What Every Patient Should Know
(14h)
How Vaccines Can Partner With Immunotherapy to Treat Lung Cancer
(15h)
FDA Approves Imfinzi Plus Chemo in GC/GEJC
(16h)
More Than a Cyst: The Fear Cancer Leaves Behind
(18h)
Basics of Squamous Cell Bladder Cancer
(19h)
AVZO-103 Wins FDA Designation for Previously Treated Urothelial Cancer
(20h)
Expert Explains Recent Advances in Early Stage Lung Cancer Surgery
(22h)
How I Navigate Grief and the Holidays After Cancer Loss
(1d)
How New Therapies Are Changing the Game for Small Cell Lung Cancer
(1d)
SANRECO Trial Explores Divesiran for Polycythemia Vera Treatment
(1d)
Voranigo is Safe and Tolerable in High-Grade IDH-Mutant Gliomas
(1d)
Sac-TMT Combo Shows Benefit in Advanced Lung Cancer Treatment
(1d)
Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL
(1d)
Expert Advice and Resources for Patients with Neuroendocrine Tumors
(2d)
Addressing Common Talquetamab Misunderstandings
(2d)
Advice for the Caregiver: Be a Patient Advocate
(2d)
Advice for the Patient Starting Treatment With Talquetamab
(2d)
Managing Taste Changes and Weight Loss During Talquetamab Treatment
(2d)
Practical Tips for Managing Nail and Skin Changes While Receiving Talquetamab
(2d)
Developing a System-Wide Protocol for Talquetamab Toxicity Management
(2d)
Contract Pharma
Sanofi and Regeneron’s Dupixent Approved in EU
(20h)
BioMed X, AbbVie Launch New Research Project Focused on Anhedonia
(22h)
The Future of Oral Solids
(1d)
Roche Adopts Veeva Vault CRM
(2d)
AstraZeneca to Invest $2B in Maryland
(2d)
Derisking Global Supply Chain Networks with Foreign Trade Zones
(4d)
AGC Biologics Enters Gene Therapy Manufacturing Agreement with AAVantgarde
(5d)
Novartis to Create New Flagship Manufacturing Hub in North Carolina
(5d)
Overcoming Solubility Challenges at Hovione’s Expanded NJ Site
(5d)
ProFound Therapeutics, Quotient Therapeutics Enter Collaborations with GSK
(6d)
Piramal’s Grangemouth, UK Facility Receives Updated MHRA GMP Certificates
(6d)
What’s Next in Pharmaceutical R&D?
(6d)
Lilly to Open Lilly Gateway Labs Site in Philadelphia
(6d)
Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer
(6d)
Primerdesign Launches Exsig Mag RapidBead Pro Extraction Kit
(6d)
EC Approves Subcutaneous Administration of Keytruda
(6d)
AGC Biologics, Repair Biotechnologies Partner to Develop & Manufacture mRNA Therapeutic
(7d)
Johnson & Johnson 3Q Results
(1w)
Agenus Taps Dr. José Iglesias as Chief Medical Affairs Officer
(1w)
Halozyme Therapeutics Acquires Elektrofi for $750M
(1w)
Pharma Times
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
(23h)
FDA approves Keytruda and Keytruda Qlex with Padcev for bladder cancer
(1d)
Academy and Wellcome strengthen partnership with £27m agreement to boost UK health research
(2d)
Bayer’s asundexian shows promise in landmark phase 3 stroke study
(2d)
Gobivaz approved across Europe as first Simponi biosimilar
(6d)
Poolbeg granted European patent for POLB 001
(6d)
TARA-002 shows strong early results in trial for paediatric lymphatic malformations
(6d)
Libtayo approved in EU as first adjuvant immunotherapy for high-risk CSCC
(7d)
Cellbyte raises $2.75m to slash drug launch timelines with AI
(1w)
GSK and Imperial launch £45m AI-powered AMR research drive
(1w)
Scottish Brain Sciences opens new Alzheimer’s research centre in Aberdeen
(1w)
High dose nusinersen regimen receives positive CHMP opinion
(1w)
Eisai shares long-term data on lecanemab at neurology congress
(2w)
Mursla Bio partners with global pharma to advance precision medicine in liver disease
(2w)
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
(2w)
Adocia unveils new long-acting peptide platform for diabetes and obesity
(2w)
Real-world data shows AUSTEDO improves life for patients with tardive dyskinesia
(2w)
MSD’s oral cholesterol drug shows promise in late-stage trial
(2w)
MiNK Therapeutics unveils promising results for agenT-797 in resistant cancers
(2w)
Procysbi approved for NHS Scotland use in rare kidney disorder
(2w)
Medcity News
FamilyWell Health Lands $8M to Grow Women’s Mental Health Support
(12h)
Boise’s Leading Sedation Dentistry Practices: A Comprehensive Guide
(12h)
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?
(12h)
The Opportunity being Missed in UK Healthcare Buyouts
(21h)
Orthopedics Cracked the Code on Wait Times: Here’s How They Did It
(21h)
MedCity Pivot Podcast: Could This Device Make Managing Brain Health Easier?
(1d)
Quality Isn’t Just a Checkbox — Can Better Workforce Skills Drive Lower Costs?
(1d)
Lawmakers Introduce Multiple Bills Aimed at Medicare Advantage Reform
(1d)
Precision vs. Power: How Nimble Innovators Are Expanding Possibilities in Surgical Robotics
(1d)
How Hospitals Can Blunt the Effects of Tariffs
(2d)
Restoring Affordability to Employer Health Plans
(2d)
How Oura Expanded from Wellness to Healthcare
(2d)
Could Trump do for Branded Expensive Drugs What He Just Did for GLP-1s?
(2d)
The VBC Paradox: How Health Systems Can Balance Inpatient Revenue With Value-Based Care Goals
(2d)
The Manager’s Heartbreak: Why Nurse Turnover Cuts So Deep
(3d)
Blue Shield of California Plan Introduces Initiative to Support Expecting Parents
(4d)
Ostro Breaks a World Record in Its Bid to Better Health AI Literacy
(4d)
Top-Rated Medical Alert Systems With Fall Detection: Reviews and Comparisons
(4d)
Why It’s Time to Bring HCC Coding In-House
(4d)
The New Language of Quality: What AI Is Teaching Us About Documentation
(4d)
Chemical & Engineering News
Nov. 25 Business Watch: Flexsys readies safer tire additive; Moderna halts trials of 3 mRNA drugs
(15h)
These archaea built a distinct genetic code to put pyrrolysine in proteins
(16h)
Reactions: Plastics recycling
(18h)
COP30 final agreement omits fossil fuels
(18h)
What Hitler’s DNA and the dire wolf teach us about science
(19h)
Wild seal milk rivals human milk in sugar complexity
(19h)
Molecular tools may help us locate mass graves
(1d)
Molecule-maker Onepot.AI launches with $13 million
(1d)
Ultrasensitive sensor tracks flu- and COVID-19-fighting antibodies
(1d)
Comment: Staying safe during stressful times
(1d)
New treatments for malaria offer hope
(2d)
How Disc Medicine rescued a discarded drug candidate
(2d)
Nov. 21 Policy Watch: Vaccine-autism link ‘not ruled out,’ CDC says
(4d)
A polymer for needle-free insulin delivery
(4d)
At COP30, chemical companies push biobased climate solutions
(4d)
How to prevent emerald-green oil paint from breaking down
(5d)
Volunteer Voices: A retired research scientist chats about Senior Chemist Committees
(5d)
UK committee raises alarm over science business exodus
(5d)
ACS names Arthur C. Cope Postdoctoral Fellowships in Organic Chemistry
(5d)
Obituary: Frances Zwanzig
(5d)
The Pharma Letter
Accelerated FDA approval for Otsuka’s Voyxact
(34m)
One thing the US Senate can agree on: It’s time to fix 340B
(1h)
TransCon CNP PDUFA delay likely a speed bump to approval
(1h)
AI in clinical trials: why industry must lead in shaping regulation
(18h)
Teva wins EC nod for Prolia and Xgeva biosimilars
(19h)
Otsuka files for US approval for centanafadine in ADHD
(19h)
Broader NICE recommendation for GSK’s Jemperli
(19h)
Regulatory round-up: 25 November 2025
(20h)
Zetagen raises $12.9M to transform breast cancer care
(20h)
GV20 advances ADC partnership with Mitsubishi Tanabe
(20h)
GV20 advances ADC partnership with Mitsubishi Tanabe
(20h)
Phrontline bags equity investment from Samsung Life Science Fund
(22h)
MHRA moves to reassure parents over childhood vaccine safety
(22h)
Positive results for Novo Nordisk Phase II trial with amycretin
(23h)
FDA ramps up review designations for precision oncology as ADC momentum surges
(23h)
FDA ramps up review designations for precision oncology as ADC momentum surges
(23h)
Novartis scores a first with FDA approval for Itvisma
(1d)
Aspen’s $115 million Series C to drive Parkinson's program
(1d)
New EC approval for Dupixent in CSU
(1d)
Myth vs Fact: How US government price setting impacts innovation
(1d)
Targeted Oncology
FDA Approves Durvalumab Plus FLOT in Early Stage Gastric/GEJ Cancers
(17h)
FDA Grants Fast Track Designation to AVZO-103 for Urothelial Cancer
(17h)
Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL
(18h)
NBM-BMX Earns FDA Orphan Drug Status for Uveal Melanoma
(19h)
Durvalumab/Chemoradiotherapy Fails to Meet Efficacy, Safety in PACIFIC-2 Trial
(20h)
STOMP Trial Analysis Reveals Immunomodulatory Effects of Selinexor in RRMM
(21h)
Dr Benjamin George: Cancer Care Is “Done as a Team”
(23h)
CBR Polling Shows Rapid Uptake of Darolutamide in mHSPC
(1d)
BMI in CAR T: Overweight Status Predicts Poorer Outcomes
(1d)
Understanding the Role of Mutations in Staging of Low-Risk MDS
(1d)
Cognitive Behavioral Therapy Improves Dyspnea, Trial Shows
(1d)
Isatuximab Shows Efficacy, Safety in R/R Systemic Light Chain Amyloidosis
(1d)
RP1 Plus Nivolumab Offers Hope in Anti–PD-1 Refractory Melanoma
(1d)
Visugromab Plus Nivolumab Shows Durable Response in Refractory Tumors
(2d)
The Targeted Pulse: Oncology Advancements and FDA Decisions
(3d)
Dr Hinrichs on the Future of Cell Therapy Access: From Cancer Centers to Communities
(3d)
GLP-1 RA Use Associated with Lower 5-Year Mortality in Colon Cancer
(4d)
Patient Survey Sheds Light on Critical Communication Gaps in NMIBC Care
(4d)
Combination Approaches With Systemic Immunotherapy Enhance Medical Oncologists’ Role in NMIBC
(4d)
Eflornithine/Lomustine Prolongs Survival in Recurrent mIDH Grade 3 Astrocytoma
(4d)
MedWatch
Demant took market share among US veterans in October
(3h)
Analyst impressed by Novo Nordisk's new amycretin data
(21h)
Novo Nordisk's amycretin shows weight loss of up to 14.5%
(22h)
Novo Nordisk follows competitor: New AI director to boost competitiveness
(22h)
Investors on Novo Nordisk's Alzheimer's flop: "It's fuel on the fire"
(1d)
Analyst: Novo Nordisk's core plan unaffected by disappointing Alzheimer's study
(1d)
Sanofi and Regeneron get EU approval for Dupixent as urticaria treatment
(1d)
Agilent Technologies disappoints with new earnings forecast
(1d)
Report: European biotech misses out on billions of euros
(2d)
Analyst on failed Novo study: “Really difficult to demonstrate success”
(2d)
Novo Nordisk halts Alzheimer's trial after disappointing results
(2d)
Bayer reports positive phase 3 results for stroke drug
(2d)
Nordnet: Positive Alzheimer's data could give Novo a 10% share price boost
(2d)
US Treasury Secretary announces healthcare policy moves set for release this week
(2d)
Gubra CEO after several downward adjustments: There is light at the end of the tunnel
(2d)
Eli Lilly crosses USD 1trn in value as the first pharmaceutical company ever
(2d)
Novo Nordisk has bought real estate worth DKK billions since 2021
(2d)
Novo Nordisk and Eli Lilly to sell weight loss drugs directly to employers
(2d)
Milestones overturn Lundbeck's takeover bid: Should be scrapped, according to M&A experts
(5d)
Novo Nordisk’s price war and executive charm offensive could avert sales decline
(5d)
In The Pipeline
Alzheimer's Clinical Trial Results, Sadly Running True to Form
(14h)
Alcohol And Fructose, Tangled (and Untangled?)
(1d)
Reverse Proteolysis, Will You Look At That
(4d)
Thinking About Running a Phenotypic Assay?
(1w)
LLMs for Medical Practice: Look Out
(1w)
Huge Channels or No Channels: You Pick
(2w)
Biochemical Tungsten - Really
(2w)
Reaction Stirring, Part Two
(2w)
TrkB, BDNF, and Depression
(2w)
Making Pills. But Not Making Them Here.
(3w)
Screening Without Tagging
(3w)
Sarepta: Enough, For God's Sake
(3w)
Taking It Back, The Right Way
(3w)
The Nocebo Effect Hangs Around
(4w)
A Rare Silicon Switch
(4w)
Blasting Through Cells
(4w)
mRNA Vaccines and Immuno-oncology: Good News
(1mo)
Tunnel Away
(1mo)
When Variant Proteins Aren't Actually the Variant Ones
(1mo)
Disordered Enzymes, Oh Dear
(1mo)
Pharmaphorum
Otsuka joins IgAN market with Voyxact approval in US
(46m)
Latest Medicare pricing cuts promise $12bn in savings
(1h)
Data sets up phase 3 trials for Novo's amycretin in diabetes
(22h)
NICE backs NHS use of Autolus' leukaemia CAR-T
(23h)
£800m life sciences cluster opens in London
(1d)
Innovent files high-dose mazdutide for obesity in China
(1d)
Novartis' SMA gene therapy cleared for wider use in US
(1d)
Angelini rapped for criticism of EMA approval
(2d)
Disappointment as Novo's oral GLP-1 fails in Alzheimer's
(2d)
Stroke data breathes life back into Bayer's asundexian
(2d)
J&J abandons Alzheimer's antibody in setback for tau
(2d)
Lilly becomes first $1trn+ pharma company
(2d)
Waltz dances into direct-to-employer sales of obesity drugs
(5d)
Neuralink rival Paradromics cleared to start speech trial
(5d)
Alnylam's ATTR cardiomyopathy drug backed for NHS use
(5d)
ADC specialist Solve raises $120m, and other biofinancings
(5d)
GSK unit and AnaptysBio trade lawsuits over Jemperli
(5d)
NICE backs five AI tools for bowel cancer screening
(5d)
Merck partners Valo on $3bn, AI-based Parkinson's project
(6d)
Advocate slams muted response to UK male health strategy
(6d)
Drug Discovery Weekly
10x Genomics launches international cancer research project
(20h)
Revolutionary therapy treats Hunter syndrome for first time
(20h)
DDW Highlights: 25 November 2025
(23h)
RNA-based gene therapy offers new hope for ALS treatment
(1d)
Study reveals how water influences cancer drug potency
(1d)
eBook: What’s new in neuroscience drug discovery?
(1d)
Register your interest for DDW track at SLAS2026
(1d)
Semaglutide shows no benefit in Alzheimer’s disease
(1d)
What’s new in neuroscience drug discovery?
(1d)
First patient dosed in trial of MTHFD1/2 inhibitor
(2d)
FDA approves label expansion to treat blood-clotting disorder
(2d)
World’s first liquid infliximab formulation approved for market
(2d)
DDW Turning Science into Business Symposium available on-demand
(2d)
This week in Drug Discovery (17 – 21 November)
(5d)
Mosaic Therapeutics appoints Dr Stephen Shuttleworth as CSO
(5d)
Ochre Bio and GSK complete early research into human liver
(5d)
Omlyclo set for line extension after EC approval
(5d)
Sanofi backs Lifordi with investment for arthritis trial
(5d)
GSK partners with LTZ to develop myeloid cell engagers
(6d)
EMA issues positive CHMP opinion on Minjuvi
(6d)
HIT Consultant
RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform
(6h)
Fay and Withings Partner to Connect Health Data with Personalized Nutrition Counseling
(6h)
How Optimized Print Infrastructure Closes Compliance Gaps in Healthcare
(6h)
Why Empathy, Not Just More Features, is the Fix for Patient Portals
(10h)
Greece and Sword Health to Build AI-Powered Healthcare Front Door
(22h)
Elation Health AI Saves Primary Care Clinicians Over Two Hours Daily, Reducing Burnout
(22h)
Barco and Avatar Medical Launches Glasses-Free 3D Display for Clinical Consultations
(1d)
AI Health Care Accreditation: Benefits, Considerations and Industry Leaders
(1d)
Joi + Blokes Launches “Beyond the Labs” Telehealth Program for Personalized, High-Touch Consultations
(1d)
Why Compromised OT Devices are the Biggest Cyber Risk for Hospitals
(1d)
Ceribell Receives FDA Clearance for Clarity® AI, Becoming First Point-of-Care EEG for All Ages
(1d)
SimonMed Imaging Launches AI-Powered Mobile Reports to Transform Mammography Results
(1d)
Voio Emerges from Stealth with $8.6M to Launch World’s Most Accurate Medical Imaging Model
(1d)
Why Independent Pharmacies are the Future of Personalized Care
(1d)
Home Healthcare Safety: The Four Most Dangerous Risks and How to Prevent Them
(1d)
UI Health to Deploy Abridge AI Directly into Epic EHR Enterprise-Wide
(1d)
Philips Launches Image Management 15: Zero-Footprint Web Viewer Transforms Radiology Workflows
(1d)
GE HealthCare Submits Photonova™ Spectra for FDA Clearance: Deep Silicon Detectors Power New PCCT System
(1d)
MDI NetworX Acquires Cobalt MedPlans to Expand U.S. Payer Services and AI Automation
(2d)
Affordable Med Spa Management Software: Reviews and Recommendations
(2d)
Insights: Pink Sheet
Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge
(2h)
US FDA Approves First Reformulated Rx Ranitidine, Five Years After Withdrawal
(9h)
As US FDA Turns: Can Makary, Prasad And Pazdur Make It Work?
(12h)
Obscure User Fee Provision Gives Generic Drug Sponsors More Time To Pay Fees Post-Shutdown
(12h)
EU HTA Regulation: PICO Consolidation Going Well, Analysis Feasibility A Challenge
(19h)
UK Off-Patent Industry Urges Focus On Five Priorities Ahead Of Govt Budget
(23h)
England Becomes First In Europe To Reimburse Autolus’ CAR-T Aucatzyl
(1d)
Achieving More With Less: US FDA Offers ‘Road Map’ For AI In Rare Diseases
(1d)
CBER Poised for Research Shakeup As Prasad Makes Unproven Claims About ‘Polluted Science’
(1d)
GDUFA IV: US FDA Wants to ‘Streamline’ Formal Meeting Structure
(1d)
UK Tests Standardized Site Selection Process For Streamlining Clinical Trial Setup
(1d)
US FDA Cancer Office Keeps Hemorrhaging Staff, Most Land At Industry
(4d)
US FDA’s Advertising Enforcement Crackdown Expands To Generic Drugs
(4d)
Getting Comfortable With The Black Box: Explainable AI Techniques Build Trust
(4d)
Pharma Needs Incentives To Optimize Cancer Drugs, EMA Oncology Chair Says
(4d)
EMA’s Peter Arlett Says ‘We Will Do Better’ On EU Clinical Trials
(5d)
Biologics To Dominate 2028 Medicare Negotiation Cycle As Eligibility Expands To Part B
(5d)
Sarepta’s Elevidys Post-Infusion Proximity Stay Is Lengthy For Gene Therapies
(5d)
Onshoring Incentives Among US FDA’s GDUFA IV Proposals
(5d)
Eight African Agencies Finalizing Reliance Mechanism To Speed Drug Approvals
(5d)
BioXconomy
J&J acquires Halda for $3.05bn to advance cancer treatment platform
(31m)
Curavit partners with Cenmed to enhance decentralized clinical trial logistics
(17h)
9amHealth launches ‘No-Barriers Bundle’ to expand employer access to obesity meds, virtual care
(17h)
9amHealth launches ‘No-Barriers Bundle’ to expand employer access to obesity meds, virtual care
(17h)
The silver lining in Europe's biopharma storm
(19h)
CRScube buys Mednet to expand North American market presence
(20h)
ASOs could delay blindness in children with ultra-rare genetic disease
(20h)
Ampersand merges P95 and Julius Clinical to form global CRO
(1d)
Eyes on Asia: Sanegene Bio, ABL Bio, Third Arc Bio
(2d)
GLP-1 killer? Oligo therapy hits obesity at its source
(4d)
Waltz Health launches direct-to-employer program for obesity drugs
(4d)
Life sciences sector shines at 2025 European Lifestars Awards
(5d)
Antibody invisibility cloak protects ASO therapeutics
(5d)
BMS and Sarah Cannon expand collaboration to slash trial start-up times
(6d)
Experts call for framework to identify where AI adds most value in trials
(6d)
$120M Solution: Solve Therapeutics tackle the ADC issue
(6d)
Europe's moment: Navigating opportunity in a shifting global bioeconomy
(6d)
From 'cold' to 'hot': Oncolytic peptide brings tumors out of the shadows
(1w)
From 'cold' to 'hot': Oncolytic peptide brings tumors out of the shadows
(1w)
Iambic raises $100m to advance AI drug discovery platforms
(1w)
BioCentury
Phase III comeback for Bayer’s asundexian in stroke prevention: Clinical Report
(11h)
Novartis hoping to lift SMA gene therapy sales with Itvisma approval
(12h)
Semaglutide’s Alzheimer’s miss: A case study in balancing ambition and evidence
(16h)
FDA’s moving goalposts & China’s innovation arc — a BioCentury podcast
(1d)
Versant-backed start-up Dayra emerges with Biogen partnership: Deals Report
(1d)
FDA staffing exodus degrading oversight
(1d)
DARPA vet Fisher to lead U.K. R&D funding agency ARIA
(4d)
Cautious optimism and M&A momentum — A BioCentury podcast
(4d)
Four companies raise nearly $950M in follow-ons: Public Equity Report
(4d)
Iambic: Turning AI and automation into a two-year chemistry-to-clinic cycle
(4d)
Sydnexis setback highlights FDA’s lack of transparency, concerns about shifting goalposts
(4d)
Is there still a commercial opportunity for CRISPR-Cas9 therapies? A perspective
(5d)
Al Sandrock on why neurology might finally be ready to accelerate
(5d)
First projects revealed under Flagship/GSK partnership: Venture Report
(5d)
FDA should take a more active role in updating drug labels — when there’s strong evidence
(5d)
Rep. Auchincloss accuses Makary of politicizing FDA
(6d)
Remembering Francesco Sinigaglia, a biotech pioneer in Italy
(6d)
NME approvals by FDA’s CDER reach 37, tying 2022
(6d)
Front Row with BioCentury: The Rapid Rise of Base Editing
(6d)
Genentech continues oral SERD momentum in breast cancer: Clinical Report
(1w)